Open AccessManagement of congenital dysfibrinogenemia in pregnancy: A challenging patient case
Author(s) -
Langer Megan,
Manire Meredith,
Clarkson Matthew,
Samhouri Yazan,
Shah Deep,
Bhagavatula Rama
Publication year - 2021
Publication title -
research and practice in thrombosis and haemostasis
Language(s) - English
Resource type - Journals
ISSN - 2475-0379
DOI - 10.1002/rth2.12619
Subject(s) - medicine , pregnancy , afibrinogenemia , intensive care medicine , pediatrics , tranexamic acid , tolerability , obstetrics , fibrinogen , surgery , blood loss , adverse effect , genetics , biology
Afibrinogenemia and congenital dysfibrinogenemia (CD) are rare conditions with limited information available for appropriate management. Previous case reports have demonstrated the safe and efficacious use of fibrinogen replacement therapy (FRT) as a therapeutic approach to prevent hemorrhage and fetal loss in pregnant women with CD. In this case report, we present a 28‐year‐old pregnant woman who sought testing for CD given her family history. She denied any current or previous bleeding symptoms. Laboratory testing confirmed the diagnosis of CD. She was treated with FRT and prophylactic anticoagulation starting in her third trimester. She had preterm labor that prompted an urgent cesarean section with FRT support. This case adds to the sparse literature about fibrinogen disorders in pregnancy, and highlights the benefits, safety, and tolerability of FRT and prophylactic anticoagulation in pregnant women with CD. Finally, it emphasizes the importance of a multidisciplinary team approach for an uneventful delivery.